Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NH280105 Phase 1 in Healthy Volunteers
NCT06870058Phase 1Completed
- Sponsor
- Jiangsu Nhwa Pharmaceutical
- Start
- Mar 2025
- Primary completion
- Nov 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of NH280105 in Alzheimer's disease (AD) (2 arms), sponsored by Jiangsu Nhwa Pharmaceutical. Primary endpoints: Adverse Events, Change in Laboratory Parameters and 2 more. Started Mar 2025; status: completed.
02
Drugs
NH280105
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on NCT06870058.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06870058.